Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

ALGS
Aligos Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
May 15, 2025 3:59:43 PM EDT
5.75USD+3.417%(+0.19)133,315
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 14, 2025 9:22:30 AM EDT
6.13USD+10.252%(+0.57)0
After-hours
May 15, 2025 4:51:30 PM EDT
5.75USD0.000%(0.00)216
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
08:06AM EST  Aligos Therapeutics Begins Dosing In Chronic Hepatitis B Patients In Its Phase 1 Antisense Oligonucleotide Study   Benzinga
08:00AM EST  Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete   GlobeNewswire Inc
Jan 23, 2022
01:36PM EST  Pomerantz LLP is investigating claims on behalf of investors of Aligos Therapeutics, Inc. (Aligos or the Company) (NASDAQ: ALGS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Jan 11, 2022
09:14AM EST  Aligos Therapeutics Expands Collaboration With Merck To Develop Oligonucleotide Therapies For NASH   Benzinga
09:12AM EST  Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced thatit has expanded its ongoing collaboration agreement with Merck to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis (NASH).   GlobeNewswire Inc
Jan 10, 2022
07:41AM EST  The Week Ahead In Biotech (Jan 10-15): JPMorgan Healthcare Conference Front And Center, Preannouncements Keep Coming   Benzinga
Jan 7, 2022
01:07PM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022   Benzinga
01:01PM EST  JP Morgan Downgrades Aligos Therapeutics to Neutral, Lowers Price Target to $12   Benzinga
01:00PM EST  SVB Leerink Maintains Outperform on Aligos Therapeutics, Lowers Price Target to $15   Benzinga
Jan 6, 2022
02:33PM EST  Mid-Afternoon Market Update: Gold Drops 2%; Berkeley Lights Shares Plummet   Benzinga
12:11PM EST  Mid-Day Market Update: Nasdaq Turns Higher; Vocera Communications Shares Surge   Benzinga
10:16AM EST  Mid-Morning Market Update: Markets Open Lower; Walgreens Tops Q1 Views   Benzinga
08:14AM EST  Aligos Halting Further Development Of STOPS Drug Candidate, ALG-010133   Benzinga
08:00AM EST  Aligos Halting Further Development of STOPS Drug   GlobeNewswire Inc
Dec 21, 2021
04:13PM EST  Oak Street Health, Aligos Therapeutics, CVRx, Tivity, Oyster Point Pharma To Present At JP Morgan Healthcare Conference Jan. 10-12, 2022   Benzinga
04:05PM EST  Aligos Therapeutics to Present at the 40th AnnualJ.P.   GlobeNewswire Inc
Dec 9, 2021
09:46PM EST  Aligos Therapeutics Begins Dosing With NASH Drug Candidate, ALG-055009, In Healthy Volunteers In A Phase 1 First-in-Human Study   Benzinga
08:00AM EST  Aligos Therapeutics Begins Dosing with NASH Drug Candidate,   GlobeNewswire Inc
Dec 7, 2021
08:28AM EST  Aligos Presents Update Of Chronic Hepatitis B Pipeline Portfolio At HEP DART 2021 From Dec. 5-9   Benzinga
08:00AM EST  New data from HBeAg-positive patients receiving 100 mg of ALG-000184 demonstrates similar PK and potent antiviral activity to previously reported data for HBeAg-negative patients   GlobeNewswire Inc
Nov 23, 2021
07:01AM EST  DNA Encoded Library (DEL)-Based Drug Discovery for Viral Infections and Liver Diseases   PR Newswire
Nov 22, 2021
08:00AM EST  Aligos Therapeutics to Present at the Piper Sandler 33rd Annual   GlobeNewswire Inc
Nov 18, 2021
04:05PM EST  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed Bridget Martell, MA, M.D., to the Companys board of directors.   GlobeNewswire Inc
Nov 12, 2021
08:18AM EST  Candel Therapeutics, Cue, Madrigal Pharma, F-star, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting   Benzinga
08:14AM EST  Candel Therapeutics, Cue, Madrigal Pharma, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting   Benzinga
08:00AM EST  Several clinical and nonclinical posters to be presented at the conference   GlobeNewswire Inc
Nov 8, 2021
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
Nov 5, 2021
12:06PM EDT  Looking Into Aligos Therapeutics's Return On Capital Employed   Benzinga
09:31AM EDT  Aligos Therapeutics Q3 EPS $(0.78) Beats $(0.81) Estimate   Benzinga
Nov 4, 2021
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 22, 2021
07:38AM EDT  Aligos Therapeutics Sponsored ClinicalTrials.gov Listing For Co.'s 'Study of ALG-055009 Drug to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses in Healthy Volunteers and Subjects With Hyperlipidemia'   Benzinga
Oct 14, 2021
05:00PM EDT  Aligos Therapeutics To Present Data For Portfolio Targeting Chronic Hep B, NASH At The Liver Meeting Nov. 12-15   Benzinga
04:58PM EDT  Aligos Therapeutics to Present Data for its Clinical Portfolio   GlobeNewswire Inc
Oct 11, 2021
08:14AM EDT  Aligos Therapeutics Begins Dosing With Antisense Oligonucleotide Drug Candidate, ALG-020572, In Healthy Volunteers In A Phase 1 Proof-of-Concept Study   Benzinga
08:00AM EDT  Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide   GlobeNewswire Inc
Sep 20, 2021
04:05PM EDT  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Cantor Virtual Global Healthcare Conference being held September 27-30, 2021.   GlobeNewswire Inc
Sep 9, 2021
11:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021   Benzinga
06:48AM EDT  SVB Leerink Initiates Coverage On Aligos Therapeutics with Outperform Rating, Announces Price Target of $29   Benzinga
Aug 11, 2021
09:43AM EDT  Aligos Therapeutics Sponsored Study Titled 'A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects' Posted To Clinical Trials Website   Benzinga
Aug 5, 2021
04:31PM EDT  Aligos Therapeutics Q2 EPS $(0.79) Beats $(0.81) Estimate   Benzinga
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 1, 2021
02:34PM EDT  Mid-Afternoon Market Update: Dow Gains 100 Points; NovoCure Shares Plunge   Benzinga
12:06PM EDT  Mid-Day Market Update: Crude Oil Rises Over 2%; Aligos Therapeutics Shares Slide   Benzinga
11:47AM EDT  Shares of clinical stage biopharmaceutical company Aligos Therapeutics, Inc. (ALGS) are down 18 percent on Thursday's trading. The company priced its public offering of 4.4 million shares at $19.00 per share. All the shares are being offered by the company itself. Aligos expects to generate gross proceeds of $83.6 million from the offering, which will close on July 6.   RTTNews
07:26AM EDT  Aligos Therapeutics Raises $84M Via Equity At 7% Discount   Benzinga
Jun 30, 2021
10:08PM EDT  Aligos Therapeutics Announces Pricing of $83.6 Million Public   GlobeNewswire Inc
Jun 29, 2021
08:53AM EDT  Aligos Therapeutics Presses Capital Raise Button   Benzinga
08:17AM EDT  The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout   Benzinga
Jun 28, 2021
04:11PM EDT  Aligos Therapeutics Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
04:05PM EDT  Aligos Therapeutics Inc Files For Offering 4M Shares Of Common Stock   Benzinga
Jun 21, 2021
08:15AM EDT  Aligos Therapeutics To Present Phase 1 Safety, Pharmacokinetic Data for STOPS Molecule Drug Candidate ALG-010133 And Several Nonclinical Chronic Hepatitis B Programs At Digital International Liver Congress 2021   Benzinga
08:00AM EDT  -First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients-Presentations include nonclinical data from 3 other CHB programs   GlobeNewswire Inc
Jun 14, 2021
08:09AM EDT  Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver's Digital International Liver Congress 2021   Benzinga
08:00AM EDT  Aligos Therapeutics Announces Pipeline Update and Upcoming   GlobeNewswire Inc
Jun 10, 2021
08:13AM EDT  The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal   Benzinga
07:02AM EDT  Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B Subjects at HBV-TAG Conference   Benzinga
07:00AM EDT  Subjects experienced a 2.9 log10IU/mL mean reduction in HBV DNA levels after 14 days dosing with 100 mg ALG-000184   GlobeNewswire Inc
May 20, 2021
04:05PM EDT  Aligos Therapeutics to Present at the Jefferies Virtual Healthcare   GlobeNewswire Inc
May 10, 2021
04:40PM EDT  Aligos Therapeutics Q1 EPS $(0.74) Beats $(0.90) Estimate, Sales $910.00K   Benzinga
04:17PM EDT  Aligos Therapeutics Q1 Sales $910.00K   Benzinga
04:05PM EDT  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the first quarter March 31, 2021.   GlobeNewswire Inc
04:09AM EDT  Earnings Scheduled For May 10, 2021   Benzinga
May 5, 2021
08:00AM EDT  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the companys first quarter 2021 financial results on Monday, May 10, 2021 after the close of the financial markets.   GlobeNewswire Inc
Apr 27, 2021
04:01PM EDT  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed James Scopa, J.D., MBA, to the Companys board of directors.   GlobeNewswire Inc
Apr 14, 2021
08:11AM EDT  Aligos Therapeutics Says Begins Dosing With Capsid Assembly Modulator Drug Candidate, ALG-000184, In First Cohort Of Chronic Hepatitis B Patients In Phase 1 Proof-Of-Concept Study   Benzinga
08:00AM EDT  Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator   GlobeNewswire Inc
Mar 23, 2021
04:13PM EDT  Aligos Therapeutics Q4 EPS $(1.09) Up From $(7.27) YoY   Benzinga
04:05PM EDT  Aligos Therapeutics Reports Fourth Quarter and Full Year 2020   GlobeNewswire Inc
Mar 10, 2021
08:13AM EST  Aligos Therapeutics Reports Commencement Of Dosing For First Cohort Of Chronic Hep B Patients In Ongoing Study   Benzinga
08:13AM EST  Aligos Therapeutics Begins Dosing With STOPS Molecule Drug Candidate, ALG-010133, In First Cohort Of Chronic Hepatitis B Patients In A Phase 1 Proof-Of-Concept Study   Benzinga
08:00AM EST  Aligos Therapeutics Begins Dosing with STOPS   GlobeNewswire Inc
Mar 8, 2021
08:46AM EST  Aligos Therapeutics Presents Nonclinical Data for its COVID-19   GlobeNewswire Inc
08:02AM EST  Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic Infections   Benzinga
Feb 3, 2021
08:08AM EST  Aligos Therapeutics Presents Data For Its Chronic Hepatitis B Drug Candidates At 30th Annual Conference Of Asian Pacific Association For The Study Of The Liver   Benzinga
08:00AM EST  Aligos Therapeutics Presents Data for its Chronic Hepatitis B Drug   GlobeNewswire Inc
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 7, 2021
08:00AM EST  Aligos Therapeutics to Present at the 39th Annual J.P. Morgan   GlobeNewswire Inc
Dec 17, 2020
08:01AM EST  Aligos Therapeutics Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020   Benzinga
08:00AM EST  Aligos Therapeutics Presents Update on Development of SARS-CoV-2   GlobeNewswire Inc
Dec 7, 2020
08:00AM EST  Aligos Enters into an Exclusive License and Research Collaboration   GlobeNewswire Inc
Nov 20, 2020
08:06AM EST  The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger   Benzinga
Nov 17, 2020
08:32AM EST  The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration   Benzinga
Nov 16, 2020
08:22AM EST  Aligos Therapeutics Presents Data On Chronic Hepatitis B, NASH, Hepatocellular Carcinoma Programs At AASLD's The Liver Meeting Digital Experience   Benzinga
08:00AM EST  Aligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and   GlobeNewswire Inc
Nov 13, 2020
08:12AM EST  Aligos Therapeutics Announces Presentations At Jeffries Virtual London Healthcare Conference & The Piper Sandler Annual Healthcare Conference   Benzinga
08:00AM EST  Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that management will be participating in two upcoming virtual investor conferences and invites investors to participate by webcast. Please see additional details below:   GlobeNewswire Inc
Nov 12, 2020
08:03AM EST  Aligos Therapeutics Awarded 1.8M VLAIO Grant to Advance Chronic Hepatitis B Research   Benzinga
08:00AM EST  Aligos Therapeutics is awarded 1.8M VLAIO grant   GlobeNewswire Inc
Nov 10, 2020
09:19AM EST  Jefferies Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $26   Benzinga
09:15AM EST  JP Morgan Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $33   Benzinga
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Oct 30, 2020
08:02AM EDT  Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B   Benzinga
08:00AM EDT  Aligos Therapeutics Doses First Subject in Phase 1   GlobeNewswire Inc
Oct 21, 2020
08:04AM EDT  The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings   Benzinga
Oct 16, 2020
03:34PM EDT  Aligos Therapeutics Shares Opened Earlier At $17.40, IPO Priced At $15.00/Share   Benzinga
11:46AM EDT  Aligos Shares Indicating $19 On 358K Shares   Benzinga
07:59AM EDT  Aligos Therapeutics Shares Expected To Open For Trade Today, IPO Priced At $15.00/Share   Benzinga
05:46AM EDT  Aligos Therapeutics Priced 10M Share IPO @$15/Share   Benzinga
Oct 15, 2020
10:19PM EDT  Aligos Therapeutics Announces Pricing of Initial Public Offering   GlobeNewswire Inc
Oct 11, 2020
06:35PM EDT  IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC